MGC Pharmaceuticals announced an increase in patient numbers and reported progress on its LSE listing in its September quarterly report.

MGC Pharmaceuticals (ASX:MXC) announced an increase in patient numbers and reported progress on its LSE listing in its September quarterly report.

As quoted in the press release:

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We have seen another period of excellent progress delivering on our ‘Seed to Medicine’ business strategy. We have achieved multiple milestones across our pharma business channels, the highlight being the continuing rapid growth of prescription numbers, doubling in just two weeks during September and continuing during October, which validates the quality and immediate patient demand for our phytocannabinoid based investigational medicinal products (IMP) and underpins our growth potential.

Click here to read the full press release.

MGC Pharmaceuticals Receives Approval for Distribution in Ireland

MGC Pharmaceuticals (ASX:MXC) has received formal approval from the Health Products Regulatory Authority (HPRA) in Ireland for the sale of CannEpil.

As quoted in the press release:

Keep reading... Show less

MGC Pharmaceuticals Receives Approval for Distribution in Ireland

MGC Pharmaceuticals (ASX:MXC) has received formal approval from the Health Products Regulatory Authority (HPRA) in Ireland for the sale of CannEpil.

As quoted in the press release:

Keep reading... Show less

MGC Pharma Sees Growth in Prescriptions for November

MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 26) it has seen 40 percent growth since the end of October 2019 in the number of prescribed cannabinoid medicines in Australia, the United Kingdom and Brazil.

As quoted in the press release:

Keep reading... Show less

MGC Pharma Receives First Government Grant for Clinical Trial

MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 12) it’s received funding from the Australian Commonwealth Government for its clinical trial in collaboration with the University of Notre Dame Western Australia.

As quoted in the press release:

Keep reading... Show less

How to Access Medical Cannabis in Australia

Recreational cannabis remains out of reach in Australia, but the country legalised medical cannabis in 2016, opening up access to the cannabis market for both Australians and investors alike.

Cannabis in Australia is used to treat a myriad of conditions, from epilepsy to neuropathic pain, but federal legislation has a strict hold on the distribution of cannabis in the country.

Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. However, there are signs that the limits to access are slowly lessening, including the approval of over-the-counter cannabidiol (CBD) products and new breakthroughs in government-sponsored medical cannabis research.

Keep reading... Show less

Australia Mining Update: H1 2021 in Review

Click here to read the previous Australia mining update.

After an uncertain 2020 for the Australian mining industry, the resource market showed signs of a sharp recovery in the first six months of the new year.

Prices for iron ore are supporting resource exports in the country, with many ASX-listed mining companies also posting gains year-to-date.

Here the Investing News Network looks at what's happened in Australia's mining sector so far in 2021, and what could be ahead in the second half.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

Investing in Lithium in Australia

After the country became the world’s largest lithium producer in 2018, many market participants are wondering if investing in lithium in Australia is a good option

Without a doubt, the energy revolution is here to stay, with forecasts for electric vehicle (EV) sales increasing every day. As a result, demand for lithium, a key element in the lithium-ion batteries used to power electric cars, is expected to triple by 2025 — reaching about 1 million tonnes in size.

For investors interested in getting into the space, here’s a brief overview of the basic facts to know about investing in lithium in Australia, including what stocks to keep an eye on.

Keep reading... Show less

How to Buy Bitcoin in Australia

Investors looking for decentralised assets (and potentially major gains) in a post-COVID-19 Australia are turning in droves to cryptocurrencies.

Bitcoin in particular is getting Aussies excited after its price hit record highs in March 2021, and again the next month. As a finite resource, its volatility is proving exciting for many market watchers.

For those interested in jumping into the space, the Investing News Network has put together a step-by-step guide on how to start buying bitcoin in Australia — and how to stay safe while doing so.

Keep reading... Show less

How to Access Medical Cannabis in Australia

Recreational cannabis remains out of reach in Australia, but the country legalised medical cannabis in 2016, opening up access to the cannabis market for both Australians and investors alike.

Cannabis in Australia is used to treat a myriad of conditions, from epilepsy to neuropathic pain, but federal legislation has a strict hold on the distribution of cannabis in the country.

Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. However, there are signs that the limits to access are slowly lessening, including the approval of over-the-counter cannabidiol (CBD) products and new breakthroughs in government-sponsored medical cannabis research.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

When Will Australia Legalise Recreational Cannabis?

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less

A State-by-State Guide to Cannabis in Australia

Australia made waves when it federally legalised medicinal cannabis in 2016, and its marijuana market has experienced significant growth since then.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020, while research firm Prohibition Partners indicates that Oceania’s cannabis industry is expected to be worth US$1.55 billion by 2024; medicinal cannabis is expected to account for 40 percent of the industry.

Despite that growth, the country’s cannabis industry is still young. Recreational use is not yet in sight, and even medical access remains limited and highly regulated.

Keep reading... Show less

Australian Cannabis: Forecasts, Analysis and Expert Advice

Are you ready to start investing in Australia’s growing cannabis market?

Dive right in with our FREE Special Report, Australian Cannabis: Forecasts, Analysis and Expert Advice

Keep reading... Show less

Top News

Related News